Skip to main content
Log in

Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression levels in non-small cell lung cancer—a preliminary report

  • Original Articles
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

In this study we investigated whether Tc-99m hexakis 2-methoxy isobutyl isonitrile (Tc-99m MIBI) single-photon emission computed tomography (SPECT) has a correlation with the multidrug resistance (MDR1) and multidrug resistance-associated protein (MRP1) gene expression levels in non-small cell lung cancer (NSCLC). Fifteen patients with NSCLC were studied. SPECT images were obtained 15 (early) and 120 (delayed) min after injection of Tc-99m MIBI. We chose only one transverse section and set the region of interest over the tumor and out of the body. The mean counts in the tumor on early and delayed images were corrected by using those in the background and represented as Te and Td, respectively. Resected tumor specimens were frozen with liquid nitrogen and each positive control cell line was cultured. After the total ribonucleic acid (RNA) was extracted from specimens and cell lines, the complimentary deoxyribonucleic acid (cDNA) was amplified by the reverse transcription-polymerase chain reaction (RT-PCR) method. Each product was electrophoresed and fluorointensity was measured. The gene expression level was represented as the ratio of that of the positive control cell line. Te and Td indicated a significant correlation with the MDR1 gene expression level (p=0.015 and p=0.022), but not the gene of MRP1 (p=0.100 and p=0.145). In conclusion, Te and Td are useful parameters in predicting the MDR1 gene expression level, but not MRP1 in NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Soegfried JM, Burke TG, Tritton TR. Cellular transport of anthracyclines by passive diffusion. Implications for drug resistance.Biochem Pharmacol 1985; 34: 594–598.

    Google Scholar 

  2. Susan PC, Bhardwaj G, Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line.Science 1992; 258: 1650–1654.

    Article  Google Scholar 

  3. Luker GD, Fracasso PM, Dobkin J, Piwinka WD. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibiin vivo.J Nucl Med 1997; 38: 369–372.

    PubMed  CAS  Google Scholar 

  4. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy.Pathol Res Pract 1996; 192: 768–780.

    PubMed  CAS  Google Scholar 

  5. Van Luyn MJ, Muller M, Renes J, Meijer C, Scheper RJ, Nienhuis EF, et al. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1.Int J Cancer 1998; 76: 55–62.

    Article  PubMed  Google Scholar 

  6. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201.Clin Nucl Med 1992; 17: 171–176.

    Article  PubMed  CAS  Google Scholar 

  7. Kostakoglu L, Nazenin E, Pinar K, Sevket R, Iskender S, Esmen B, et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.J Nucl Med 1997; 38: 1003–1008.

    PubMed  CAS  Google Scholar 

  8. Piwinka Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Fractional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.

    Google Scholar 

  9. Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cellsin vivo.Br J Cancer 1996; 74: 1929–1934.

    PubMed  CAS  Google Scholar 

  10. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W, et al.99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.Br J Cancer 1998; 77: 353–358.

    PubMed  CAS  Google Scholar 

  11. Moretti JL, Duran CM, Starzec A, de Beco V, Vergote J, Benazzouz F, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.J Nucl Med 1998; 39: 1214–1218.

    PubMed  CAS  Google Scholar 

  12. Strauss GM. Role of chemotherapy in stages I to III non-small cell lung cancer.Chest 1999; 116: 509S-516S.

    Article  PubMed  CAS  Google Scholar 

  13. Berger W, Elbling L, Hauptmann E, Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small cell lung cancer cells.Int J Cancer 1997; 73: 84–93.

    Article  PubMed  CAS  Google Scholar 

  14. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.Cancer Res 1995; 55: 977–984.

    Google Scholar 

  15. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate within vitro resistance to taxol and doxorubicin.Clin Cancer Res 1998; 4: 389–398.

    PubMed  CAS  Google Scholar 

  16. Del VS, Ciarmiello A, Salvatore M. Wash-out kinetics of Tc-99m MIBI and the scintigraphic determination of Pgp expression: reply [letter; comment]Eur J Nucl Med 1998; 25: 192.

    Google Scholar 

  17. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.J Nucl Med 1998; 39: 228–234.

    PubMed  CAS  Google Scholar 

  18. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results.Cancer Lett 2000; 153: 95–100.

    Article  PubMed  CAS  Google Scholar 

  19. Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar YT, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs.Clin Nucl Med 1989; 14: 333–340.

    Article  PubMed  CAS  Google Scholar 

  20. Koukourakis MI, Koukouraki S, Giatromanolaki A Skarlatos J, Georgoulias V, Karkavitsas N. Non-small cell lung cancer functional imaging: increased hexakis 2-methoxy isobutyl isonitrile tumor clearance correlates with resistance to cytotoxic treatment.Clin Cancer Res 1997; 3: 749–754.

    PubMed  CAS  Google Scholar 

  21. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.Clin Cancer Res 2000; 6: 820–824.

    PubMed  CAS  Google Scholar 

  22. Huyang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL60 cells.Leukemia 1997; 11: 253–257.

    Article  Google Scholar 

  23. Del Vecchio S, Ciarmiello A, Pace L, Poenta MI, Carriero MV, Mainolfi C, et al. Tractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.J Nucl Med 1997; 38: 1348–1351.

    PubMed  Google Scholar 

  24. Delmon Moingeon LI, Piwnica Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell linesin vitro.Cancer Res 1990; 50: 2198–2202.

    PubMed  CAS  Google Scholar 

  25. Chiu ML, Kronauge JF, Piwnica Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts.J Nucl Med 1990; 31: 1646–1653.

    PubMed  CAS  Google Scholar 

  26. Ceriani L, Giovanella L, Bandera M, Beghe B, Ortelli M, Roncari G. Semi-quantitative assessment of99mTc-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy.Nucl Med Commun 1997; 18: 1087–1097.

    Article  PubMed  CAS  Google Scholar 

  27. Sasaki M, Kuwabara Y, Ichiya Y, Yoshida T, Nakagawa M, Soeda H, et al. Prediction of the chemosensitivity of lung cancer by99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT.J Nucl Med 1999; 40: 1778–1783.

    PubMed  CAS  Google Scholar 

  28. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.Clin Cancer Res 1995; 1: 1301–1310.

    PubMed  CAS  Google Scholar 

  29. Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.Ann Oncol 1996; 7: 75–81.

    PubMed  CAS  Google Scholar 

  30. Giaccone G, van Ark OJ, Rubio GJ, Gazder AF, Broxterman HJ, Dingemans AM, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.Int J Cancer 1996; 66: 760–767.

    Article  PubMed  CAS  Google Scholar 

  31. Wright SR, Boag AH, Valdimarsson G, Hipfner DR, Campling BG, Cole SP, et al. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.Clin Cancer Res 1998; 4: 2279–2289.

    PubMed  CAS  Google Scholar 

  32. Sugawara I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A, et al. Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.Int J Cancer 1995; 64: 322–325.

    Article  PubMed  CAS  Google Scholar 

  33. Shih WJ, Rastogi A, Stipp V, Gross KK, Coupal JJ, Magoun S. Tc-99m MIBI thoracic SPECT for the detection of intrathoracic tumor masses.Clin Nucl Med 1998; 23: 594–600.

    Article  PubMed  CAS  Google Scholar 

  34. Nishiyama Y, Kawasaki Y, Yamamoto Y, Fukunaga K, Satoh K, Takashima H, et al. Technetium-99m-MIBI and thallium-201 scintigraphy of primary lung cancer.J Nucl Med 1997; 38: 1358–1361.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Taizo Aratani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aratani, T., Narabayashi, I., Komori, T. et al. Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression levels in non-small cell lung cancer—a preliminary report. Ann Nucl Med 15, 313–319 (2001). https://doi.org/10.1007/BF02988237

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02988237

Key words

Navigation